Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX (HORIZON III)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00384176
First received: October 3, 2006
Last updated: September 23, 2014
Last verified: September 2014
  Purpose

The purpose of this study is to see if Cediranib in combination with FOLFOX is effective in treating metastatic colorectal cancer and to see how it compares with Avastin (Bevacizumab) in combination with FOLFOX.


Condition Intervention Phase
Colorectal Cancer
Drug: Cediranib
Drug: Bevacizumab
Drug: 5-fluorouracil ( in FOLFOX)
Drug: Leucovorin (in FOLFOX)
Drug: Oxaliplatin (in FOLFOX)
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Progression Free Survival [ Time Frame: Baseline then at Weeks 8, 16, 24 and then every 12 weeks until progression ] [ Designated as safety issue: No ]
    Progression is defined as the number of months from randomisation until progressive disease based on RECIST (progression of target lesions, clear progression of existing non-target lesions or the appearance of one or more new lesions) or death in the absence of progression.


Secondary Outcome Measures:
  • Overall Survival [ Time Frame: Randomisation until data cut-off ] [ Designated as safety issue: No ]
    Number of months from randomisation to the date of death from any cause

  • Objective Response Rate [ Time Frame: Up until data cut-off ] [ Designated as safety issue: No ]

    Objective response rate is Complete Response (CR) + Partial Response (PR) as defined below:

    CR = Disappearance of all target lesions. PR = At least a 30% decrease in the sum of longest diameters (LDs) of target lesions, taking as reference the baseline sum of LDs.


  • Duration of Response [ Time Frame: Up until data cut-off date of 15/11/2007 ] [ Designated as safety issue: No ]
    Duration of Response is calculated as the time from the first recording of CR/PR until the patient progresses, regardless of whether the patient was still taking study medication. Only confirmed responses are included in the calculation. For patients who had not progressed, the end date used in the calculation of duration of response is the data cut-off date of 15th November 2009.

  • Percentage Change in Tumour Size [ Time Frame: Baseline to Week 8 ] [ Designated as safety issue: No ]
    Percentage change in tumour size from baseline to first RECIST assessment (Week 8) ((Week 8 - baseline)/baseline)*100

  • Time to Worsening of Health Related Quality of Life (QOL) Based on the FACT Colorectal Symptom Index (FCSI) [ Time Frame: Baseline through to data cut-off ] [ Designated as safety issue: No ]
    Time to worsening of symptoms, as measured by the FACT colorectal symptom index (FCSI), will be defined as the time when a sustained clinically important deterioration in the total score from the FCSI has been recorded.


Enrollment: 1814
Study Start Date: August 2006
Estimated Study Completion Date: December 2014
Primary Completion Date: November 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Bevacizumab + FOLFOX
Drug: Bevacizumab
intravenous infusion
Other Name: Avastin®
Drug: 5-fluorouracil ( in FOLFOX)
intravenous infusion
Other Name: 5-FU
Drug: Leucovorin (in FOLFOX)
intravenous infusion
Drug: Oxaliplatin (in FOLFOX)
intravenous infusion
Other Name: Eloxatin®
Experimental: 2
Cediranib + FOLFOX
Drug: Cediranib
oral tablet once daily
Other Names:
  • RECENTIN™
  • AZD2171
Drug: 5-fluorouracil ( in FOLFOX)
intravenous infusion
Other Name: 5-FU
Drug: Leucovorin (in FOLFOX)
intravenous infusion
Drug: Oxaliplatin (in FOLFOX)
intravenous infusion
Other Name: Eloxatin®

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Clinical Diagnosis of colon or rectal cancer
  • No prior systemic therapy for metastatic disease. Any adjuvant/neoadjuvant oxaliplatin therapy must have been received >12 months prior to study entry and adjuvant/neoadjuvant 5-FU must have been received >6 months prior to study entry.

Exclusion Criteria:

  • Prior treatment with a VEGF Inhibitor, including bevacizumab and cediranib.
  • Poorly controlled hypertension
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00384176

  Hide Study Locations
Locations
United States, Alabama
Research Site
Birmingham, Alabama, United States
United States, Arizona
Research Site
Tucson, Arizona, United States
United States, California
Research Site
Palm Springs, California, United States
Research Site
San Diego, California, United States
United States, Florida
Research Site
Fort Meyers, Florida, United States
Research Site
Port St Lucie, Florida, United States
United States, Illinois
Research Site
Galesburg, Illinois, United States
Research Site
Quincy, Illinois, United States
United States, Indiana
Research Site
Layfayette, Indiana, United States
United States, Louisiana
Research Site
Alexandria, Louisiana, United States
United States, Michigan
Research Site
Ann Arbor, Michigan, United States
United States, North Carolina
Research Site
Fayetteville, North Carolina, United States
United States, North Dakota
Research Site
Bismarck, North Dakota, United States
United States, South Carolina
Research Site
Hilton Head Island, South Carolina, United States
Australia
Research Site
Ashford, Australia
Research Site
Bedford Park, Australia
Research Site
Bendigo, Australia
Research Site
Box Hill, Australia
Research Site
Camperdown, Australia
Research Site
Coffs Harbour, Australia
Research Site
Darlinghurst, Australia
Research Site
East-Melbourne, Australia
Research Site
Epping, Australia
Research Site
Herston, Australia
Research Site
Hobart, Australia
Research Site
Hornsby, Australia
Research Site
Kogarah, Australia
Research Site
Lismore, Australia
Research Site
Malvern, Australia
Research Site
Nedlands, Australia
Research Site
Port Macquarie, Australia
Research Site
Randwick, Australia
Research Site
South Brisbane, Australia
Research Site
St. Leonards, Australia
Research Site
Tamworth, Australia
Research Site
Waratah, Australia
Research Site
Wodonga, Australia
Research Site
Woodville South, Australia
Austria
Research Site
Innsbruck, Austria
Research Site
Kundratstrasse 3, Austria
Research Site
Salzburg, Austria
Research Site
Wels, Austria
Research Site
Wien, Austria
Belgium
Research Site
Bonheiden, Belgium
Research Site
Brugge, Belgium
Research Site
Brussels (Woluwé-St-Lambert), Belgium
Research Site
Edegem, Belgium
Research Site
Gent, Belgium
Research Site
Ghent, Belgium
Research Site
Kortrijk, Belgium
Research Site
Leuven, Belgium
Research Site
Roeselare, Belgium
Canada, Alberta
Research Site
Calgary, Alberta, Canada
Research Site
Edmonton, Alberta, Canada
Canada, British Columbia
Research Site
Vancouver, British Columbia, Canada
Canada, Nova Scotia
Research Site
Sydney, Nova Scotia, Canada
Canada, Ontario
Research Site
Newmarket, Ontario, Canada
Research Site
Scarborough, Ontario, Canada
Canada, Quebec
Research Site
Levis, Quebec, Canada
Research Site
Montreal, Quebec, Canada
Canada
Research Site
Quebec, Canada
Czech Republic
Research Site
Brno, Czech Republic
Research Site
Chomutov, Czech Republic
Research Site
Kutna Hora, Czech Republic
Research Site
Nova Ves pod Plesi, Czech Republic
Research Site
Pardubice, Czech Republic
Research Site
Tabor, Czech Republic
Egypt
Research Site
Alexandria, Egypt
Research Site
Cairo, Egypt
Finland
Research Site
Helsinki, Finland
Research Site
Turku, Finland
Research Site
Vaasa, Finland
France
Research Site
La Roche S YON, France
Research Site
Marseille Cedex 08, France
Research Site
Nantes,, France
Research Site
Paris, France
Research Site
Paris Cedex 15, France
Research Site
Saint Gregoire, France
Germany
Research Site
Dresden, Germany
Research Site
Essen, Germany
Research Site
Freiburg, Germany
Research Site
Halle, Germany
Research Site
Hannover, Germany
Research Site
Heidelberg, Germany
Research Site
München, Germany
Research Site
Tübingen, Germany
Hungary
Research Site
Budapest, Hungary
Research Site
Debrecen, Hungary
Research Site
Pécs, Hungary
Research Site
Szeged, Hungary
Research Site
Tatabánya, Hungary
India
Research Site
Bangalore, India
Research Site
Bhopal, India
Research Site
Chennai, India
Research Site
Hyderabad, India
Research Site
Jaipur, India
Research Site
Kolkata, India
Research Site
Pune, India
Research Site
Sheikhpura, India
Israel
Research Site
Holon, Israel
Research Site
Kfar-saba, Israel
Research Site
Petah Tikva, Israel
Research Site
Tel Aviv, Israel
Research Site
Tel-Hashomer, Israel
Research Site
Tiberias, Israel
Italy
Research Site
Ancona, Italy
Research Site
Genova, Italy
Research Site
Napoli, Italy
Research Site
Roma, Italy
Research Site
Rozzano, Italy
Latvia
Research Site
Riga, Latvia
Malta
Research Site
Floriana, Malta
Philippines
Research Site
Cebu City, Philippines
Research Site
Davao City, Philippines
Research Site
Molo, Philippines
Research Site
Quezon City, Philippines
Poland
Research Site
Bytom, Poland
Research Site
Elblag, Poland
Research Site
Kraków, Poland
Research Site
Lublin, Poland
Research Site
Poznań, Poland
Research Site
Rybnik, Poland
Russian Federation
Research Site
Barnaul, Russian Federation
Research Site
Novosibirsk, Russian Federation
Research Site
Omsk, Russian Federation
Research Site
Tomsk, Russian Federation
Research Site
Tumen, Russian Federation
Slovakia
Research Site
Bratislava, Slovakia
Research Site
Kosice, Slovakia
Research Site
Nitra, Slovakia
Research Site
Presov, Slovakia
South Africa
Research Site
Cape Town, South Africa
Research Site
Polokwane, South Africa
Research Site
Port Elizabeth, South Africa
Research Site
Pretoria, South Africa
Spain
Research Site
A Coruña, Spain
Research Site
Córdoba, Spain
Research Site
Granollers, Spain
Research Site
Hospitalet de Llobregat(Barcel, Spain
Research Site
Madrid, Spain
Research Site
Manresa, Spain
Research Site
Oviedo, Spain
Research Site
Valencia, Spain
Research Site
Zaragoza, Spain
Taiwan
Research Site
Tainan, Taiwan
Research Site
Taipei, Taiwan
Thailand
Research Site
Chiang Mai, Thailand
Research Site
Rachathewi, Thailand
Research Site
Songkla, Thailand
Turkey
Research Site
Izmir, Turkey
Ukraine
Research Site
Cherkassy, Ukraine
Research Site
Chernigiv, Ukraine
Research Site
Chernivtsi, Ukraine
Research Site
Dnipropetrovsk, Ukraine
Research Site
Donetsk, Ukraine
Research Site
Ivano-Frankivsk, Ukraine
Research Site
Kharkiv, Ukraine
Research Site
Kharkov, Ukraine
Research Site
Kherson, Ukraine
Research Site
Kiev, Ukraine
Research Site
Kyiv, Ukraine
Research Site
Lugansk, Ukraine
Research Site
Lviv, Ukraine
Research Site
Poltava, Ukraine
Research Site
Simferopol, Ukraine
Research Site
Sumy, Ukraine
Research Site
Ternopil, Ukraine
Research Site
Uzhgorod, Ukraine
United Kingdom
Research Site
Bebington, United Kingdom
Research Site
Bradford, United Kingdom
Research Site
Ipswich, United Kingdom
Research Site
London, United Kingdom
Research Site
Maidstone, United Kingdom
Research Site
Newcastle Upon Tyne, United Kingdom
Research Site
Northwood, United Kingdom
Research Site
Stockport, United Kingdom
Research Site
Sutton, United Kingdom
Vietnam
Research Site
Hanoi city, Vietnam
Research Site
Ho Chi Minh, Vietnam
Research Site
Ho Chi Minh city, Vietnam
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Jane Robertson AstraZeneca
  More Information

Additional Information:
No publications provided by AstraZeneca

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT00384176     History of Changes
Other Study ID Numbers: D8480C00013, Eudract Number 2005-003440-66
Study First Received: October 3, 2006
Results First Received: March 7, 2012
Last Updated: September 23, 2014
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
Austria: Federal Ministry for Health and Women
Czech Republic: State Institute for Drug Control
Belgium: Ministry of Social Affairs, Public Health and the Environment
United States: Food and Drug Administration

Keywords provided by AstraZeneca:
Metastatic Colorectal Cancer
RECENTIN

Additional relevant MeSH terms:
Colorectal Neoplasms
Colonic Diseases
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Intestinal Diseases
Intestinal Neoplasms
Neoplasms
Neoplasms by Site
Rectal Diseases
Bevacizumab
Cediranib
Fluorouracil
Oxaliplatin
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Enzyme Inhibitors
Growth Inhibitors
Growth Substances
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protein Kinase Inhibitors
Therapeutic Uses

ClinicalTrials.gov processed this record on November 24, 2014